Pharmaceutical stocks underperform in 2026 due to pricing reform

If Trump-backed reforms gain traction, pharmaceutical companies would face margin pressure from Medicare price negotiations and caps. Stocks like Pfizer, Merck, and Eli Lilly would likely underperform the broader market.

Implied probability (Yes)

70%